Pfizer, Summit and Therapeutics

Pfizer: What The Summit Therapeutics Deal Brings
Pfizer partners with Summit Therapeutics to advance cancer treatments using ADCs and ivonescimab. Click here to find out why PFE stock is a Buy.
Summit Therapeutics announces clinical trial collaboration with Pfizer
Summit Therapeutics (SMMT) announced a clinical trial collaboration with Pfizer (PFE) to evaluate ivonescimab, an investigational PD-1 / VEGF
Summit Therapeutics, Pfizer to Study Ivonescimab/ADC Combos
Summit Therapeutics and Pfizer will work together to study Summit's promising cancer drug candidate ivonescimab and Pfizer's antibody drug conjugates, or ADCs, in solid tumors.
Summit Therapeutics advances ivonescimab with Pfizer collaboration and expanded trials
Q4 2024 Management View Co-CEO Bob Duggan emphasized recent milestones, including a clinical trial collaboration with Pfizer to evaluate ivonescimab in combination with Pfizer’s antibody-drug conjugates (ADCs) for solid tumor treatments.
Summit Therapeutics shares rise on Pfizer trial collaboration
Summit's Co-CEOs, Bob Duggan and Dr. Maky Zanganeh, expressed optimism about the collaboration's ability to accelerate the development of ivonescimab, particularly in non-small cell lung cancer and other solid tumors. They emphasized the importance of novel mechanisms in making a significant impact for cancer patients and physicians.
Summit Therapeutics jumps 5% to $23.19 after trial pact with Pfizer
EST Summit Therapeutics (SMMT) jumps 5% to $23.19 after trial pact with Pfizer (PFE)Discover the Best Stocks and Maximize Your Portfolio:
Pharmaceutical Technology35m
Pfizer sets sights on Summit’s bispecific in combo with its ADCs
Pfizer has signed a deal with Summit Therapeutics to assess the efficacy of Summit’s ivonescimab in combination with several ...
Summit Therapeutics Stock Sinks as Firm Reports Widening Loss
Key Takeaways Summit Therapeutics shares dropped 14% Monday as it reported a fourth-quarter adjusted loss nearly double that ...
FierceBiotech4h
Pfizer to test Summit’s white-hot bispecific with ADCs
Ivonescimab remains the frontrunner, with Summit on track to report topline data from a phase 3 non-small cell lung cancer ...
Summit Therapeutics Shares Down as 4Q Loss Widens
Summit Therapeutics shares fell after the company reported a wider loss in the fourth quarter. Shares were trading 14% lower at $19.11. The biopharmaceutical oncology company reported a loss of $61.2 ...
ENDPOINTS NEWS5h
Pfiz­er wants in on Sum­mit’s goal to beat Keytru­da via ADC com­bos
With help from its $43 billion Seagen merger, Pfizer will contribute its antibody-drug conjugates to Summit Therapeutics' ...
Joplin Globe3h
Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference
Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the TD Cowen 45 th Annual Health ...